Literature DB >> 1879095

Ethnic differences in drug disposition and responsiveness.

A J Wood1, H H Zhou.   

Abstract

Interethnic differences are important factors accounting for interindividual variations in drug responsiveness. However, these differences in drug response have been a relatively neglected area of investigation, so that similar doses are prescribed to different ethnic populations without consideration of interethnic pharmacokinetic and pharmacodynamic variation. With the increased recognition of genetically determined polymorphism in metabolising ability as an important factor in drug disposition, concern has developed for the importance of individualising drug dose to account for racial differences. The recognition of these differences in drug disposition and responses calls into question the failure of drug licensing authorities to demand information on dosage, efficacy and toxicity in different ethnic groups, and to accept data from limited ethnic groups such as Caucasians. This article reviews the evidence for ethnic differences in drug disposition and sensitivity and should encourage further investigations to elucidate the extent of such differences, their causes and their therapeutic impact.

Entities:  

Mesh:

Year:  1991        PMID: 1879095     DOI: 10.2165/00003088-199120050-00002

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  165 in total

1.  Pharmacokinetics of oral propranolol in chronic renal disease.

Authors:  D T Lowenthal; W A Briggs; T P Gibson; H Nelson; W J Cirksena
Journal:  Clin Pharmacol Ther       Date:  1974-11       Impact factor: 6.875

2.  The relationship between debrisoquine oxidation phenotype and the pharmacokinetics and pharmacodynamics of propranolol.

Authors:  M S Lennard; P R Jackson; S Freestone; G T Tucker; L E Ramsay; H F Woods
Journal:  Br J Clin Pharmacol       Date:  1984-06       Impact factor: 4.335

3.  Interindividual and interethnic differences in the demethylation and glucuronidation of codeine.

Authors:  Q Y Yue; J O Svensson; C Alm; F Sjöqvist; J Säwe
Journal:  Br J Clin Pharmacol       Date:  1989-12       Impact factor: 4.335

Review 4.  Variations between individuals and populations in the acetylation of isoniazid and its significance for the treatment of pulmonary tuberculosis.

Authors:  G A Ellard
Journal:  Clin Pharmacol Ther       Date:  1976-05       Impact factor: 6.875

5.  A family study of genetic and environmental factors determining polymorphic hydroxylation of debrisoquin.

Authors:  E Steiner; L Iselius; G Alván; J Lindsten; F Sjöqvist
Journal:  Clin Pharmacol Ther       Date:  1985-10       Impact factor: 6.875

6.  Differences in stereoselective disposition of propranolol do not explain sensitivity differences between white and Chinese subjects: correlation between the clearance of (-)- and (+)-propranolol.

Authors:  H H Zhou; A J Wood
Journal:  Clin Pharmacol Ther       Date:  1990-06       Impact factor: 6.875

7.  Defective N-oxidation of sparteine in man: a new pharmacogenetic defect.

Authors:  M Eichelbaum; N Spannbrucker; B Steincke; H J Dengler
Journal:  Eur J Clin Pharmacol       Date:  1979-09       Impact factor: 2.953

8.  S-mephenytoin 4-hydroxylase is inherited as an autosomal-recessive trait in Japanese families.

Authors:  S A Ward; F Goto; K Nakamura; E Jacqz; G R Wilkinson; R A Branch
Journal:  Clin Pharmacol Ther       Date:  1987-07       Impact factor: 6.875

9.  Trial of atenolol and chlorthalidone for hypertension in black South Africans.

Authors:  Y K Seedat
Journal:  Br Med J       Date:  1980-11-08

10.  Timolol and atenolol: relationships between oxidation phenotype, pharmacokinetics and pharmacodynamics.

Authors:  R V Lewis; M S Lennard; P R Jackson; G T Tucker; L E Ramsay; H F Woods
Journal:  Br J Clin Pharmacol       Date:  1985-03       Impact factor: 4.335

View more
  29 in total

1.  Ethnic differences in the neuroleptic treatment of schizophrenia.

Authors:  P Ruiz; R V Varner; D R Small; B A Johnson
Journal:  Psychiatr Q       Date:  1999

2.  Pharmacokinetics of tolbutamide in ethnic Chinese.

Authors:  A S Gross; S Bridge; G M Shenfield
Journal:  Br J Clin Pharmacol       Date:  1999-02       Impact factor: 4.335

Review 3.  Recommendations of the clinical trials consensus panel. National Medical Association.

Authors: 
Journal:  J Natl Med Assoc       Date:  2000-10       Impact factor: 1.798

Review 4.  Racial and ethnic differences in response to medicines: towards individualized pharmaceutical treatment.

Authors:  Valentine J Burroughs; Randall W Maxey; Richard A Levy
Journal:  J Natl Med Assoc       Date:  2002-10       Impact factor: 1.798

5.  An ECOG phase II study of amonafide in unresectable or recurrent carcinoma of the head and neck (PB390). Eastern Cooperative Oncology Group.

Authors:  A N Leaf; D Neuberg; E L Schwartz; S Wadler; P S Ritch; J P Dutcher; G L Adams
Journal:  Invest New Drugs       Date:  1997       Impact factor: 3.850

Review 6.  Ethnic or racial differences revisited: impact of dosage regimen and dosage form on pharmacokinetics and pharmacodynamics.

Authors:  Mei-Ling Chen
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

Review 7.  Interethnic differences in drug metabolism: influence of genetic and environmental factors on debrisoquine hydroxylation phenotype.

Authors:  A Llerena; J Cobaleda; C Martínez; J Benítez
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1996 Apr-Jun       Impact factor: 2.441

Review 8.  Clinical pharmacokinetic considerations in the elderly. An update.

Authors:  M T Kinirons; P Crome
Journal:  Clin Pharmacokinet       Date:  1997-10       Impact factor: 6.447

Review 9.  Interethnic differences in pharmacokinetics of antibacterials.

Authors:  Danny Tsai; Janattul-Ain Jamal; Joshua S Davis; Jeffrey Lipman; Jason A Roberts
Journal:  Clin Pharmacokinet       Date:  2015-03       Impact factor: 6.447

10.  Effect of race and sex on single and multiple dose pharmacokinetics of desloratadine.

Authors:  Melton Affrime; Christopher Banfield; Samir Gupta; Albert Cohen; Tanya Boutros; Mohan Thonoor; Mitchell Cayen
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.